Is there still a role for axillary dissection in breast cancer surgery?

Travis E. Grotz, Judy C Boughey

Research output: Contribution to journalArticle

Abstract

The operative management of breast cancer has followed a natural progression toward less invasive techniques over the past century as chemotherapy, hormonal therapy, and radiation therapy have become more effective and used more frequently. Sentinel lymph node (SLN) biopsy in clinically node-negative patients has replaced axillary lymph node dissection (ALND), resulting in improved staging and decreased morbidity. ALND has remained important for patients with clinically involved lymph nodes or positive SLN; however, new evidence from the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial has identified a subset of patients with breast cancer who do not benefit from axillary lymphadenectomy following a positive SLN biopsy. These results are practice changing and need to be analyzed within the context of patient selection and multidisciplinary treatment. Herein, we review the emerging data regarding the benefits and indications for axillary lymphadenectomy in the modern era of multidisciplinary breast cancer management.

Original languageEnglish (US)
Pages (from-to)110-118
Number of pages9
JournalCurrent Breast Cancer Reports
Volume4
Issue number2
DOIs
StatePublished - Jun 2012

Fingerprint

Lymph Node Excision
Dissection
Breast Neoplasms
Sentinel Lymph Node Biopsy
Patient Selection
Radiotherapy
Lymph Nodes
Morbidity
Drug Therapy
Therapeutics

Keywords

  • Axillary lymphadenectomy
  • Lymphatic mapping
  • Nodal recurrence
  • Regional recurrence
  • Sentinel lymph node
  • Sentinel lymph node biopsy
  • Staging
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Is there still a role for axillary dissection in breast cancer surgery? / Grotz, Travis E.; Boughey, Judy C.

In: Current Breast Cancer Reports, Vol. 4, No. 2, 06.2012, p. 110-118.

Research output: Contribution to journalArticle

@article{8f8b785bc5e34dfe961ff48b68e4a1cc,
title = "Is there still a role for axillary dissection in breast cancer surgery?",
abstract = "The operative management of breast cancer has followed a natural progression toward less invasive techniques over the past century as chemotherapy, hormonal therapy, and radiation therapy have become more effective and used more frequently. Sentinel lymph node (SLN) biopsy in clinically node-negative patients has replaced axillary lymph node dissection (ALND), resulting in improved staging and decreased morbidity. ALND has remained important for patients with clinically involved lymph nodes or positive SLN; however, new evidence from the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial has identified a subset of patients with breast cancer who do not benefit from axillary lymphadenectomy following a positive SLN biopsy. These results are practice changing and need to be analyzed within the context of patient selection and multidisciplinary treatment. Herein, we review the emerging data regarding the benefits and indications for axillary lymphadenectomy in the modern era of multidisciplinary breast cancer management.",
keywords = "Axillary lymphadenectomy, Lymphatic mapping, Nodal recurrence, Regional recurrence, Sentinel lymph node, Sentinel lymph node biopsy, Staging, Survival",
author = "Grotz, {Travis E.} and Boughey, {Judy C}",
year = "2012",
month = "6",
doi = "10.1007/s12609-012-0074-8",
language = "English (US)",
volume = "4",
pages = "110--118",
journal = "Current Breast Cancer Reports",
issn = "1943-4588",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Is there still a role for axillary dissection in breast cancer surgery?

AU - Grotz, Travis E.

AU - Boughey, Judy C

PY - 2012/6

Y1 - 2012/6

N2 - The operative management of breast cancer has followed a natural progression toward less invasive techniques over the past century as chemotherapy, hormonal therapy, and radiation therapy have become more effective and used more frequently. Sentinel lymph node (SLN) biopsy in clinically node-negative patients has replaced axillary lymph node dissection (ALND), resulting in improved staging and decreased morbidity. ALND has remained important for patients with clinically involved lymph nodes or positive SLN; however, new evidence from the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial has identified a subset of patients with breast cancer who do not benefit from axillary lymphadenectomy following a positive SLN biopsy. These results are practice changing and need to be analyzed within the context of patient selection and multidisciplinary treatment. Herein, we review the emerging data regarding the benefits and indications for axillary lymphadenectomy in the modern era of multidisciplinary breast cancer management.

AB - The operative management of breast cancer has followed a natural progression toward less invasive techniques over the past century as chemotherapy, hormonal therapy, and radiation therapy have become more effective and used more frequently. Sentinel lymph node (SLN) biopsy in clinically node-negative patients has replaced axillary lymph node dissection (ALND), resulting in improved staging and decreased morbidity. ALND has remained important for patients with clinically involved lymph nodes or positive SLN; however, new evidence from the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial has identified a subset of patients with breast cancer who do not benefit from axillary lymphadenectomy following a positive SLN biopsy. These results are practice changing and need to be analyzed within the context of patient selection and multidisciplinary treatment. Herein, we review the emerging data regarding the benefits and indications for axillary lymphadenectomy in the modern era of multidisciplinary breast cancer management.

KW - Axillary lymphadenectomy

KW - Lymphatic mapping

KW - Nodal recurrence

KW - Regional recurrence

KW - Sentinel lymph node

KW - Sentinel lymph node biopsy

KW - Staging

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84863715506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863715506&partnerID=8YFLogxK

U2 - 10.1007/s12609-012-0074-8

DO - 10.1007/s12609-012-0074-8

M3 - Article

VL - 4

SP - 110

EP - 118

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

IS - 2

ER -